These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 15791510

  • 1. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
    De Wals P, Deceuninck G, De Serres G, Boivin JF, Duval B, Remis R, Massé R.
    Clin Infect Dis; 2005 Apr 15; 40(8):1116-22. PubMed ID: 15791510
    [Abstract] [Full Text] [Related]

  • 2. Meningococcal C vaccines: the Canadian experience.
    De Wals P.
    Pediatr Infect Dis J; 2004 Dec 15; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [Abstract] [Full Text] [Related]

  • 3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.
    Pediatrics; 2005 Aug 15; 116(2):e285-94. PubMed ID: 16061582
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
    De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G.
    Pediatr Infect Dis J; 2011 Jul 15; 30(7):566-9. PubMed ID: 21326136
    [Abstract] [Full Text] [Related]

  • 5. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
    Cardeñosa N, Domínguez A, Martínez A, Alvarez J, Pañella H, Godoy P, Minguell S, Camps N, Vázquez JA, Working Group on Meningococcal Disease.
    Infection; 2003 Dec 15; 31(6):392-7. PubMed ID: 14735381
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P, De Serres G, Niyonsenga T.
    JAMA; 2001 Jan 10; 285(2):177-81. PubMed ID: 11176810
    [Abstract] [Full Text] [Related]

  • 7. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, Canadian Immunization Monitoring Program, Active (IMPACT).
    Pediatr Infect Dis J; 2009 Mar 10; 28(3):220-4. PubMed ID: 19209096
    [Abstract] [Full Text] [Related]

  • 8. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
    Larrauri A, Cano R, García M, Mateo Sd.
    Vaccine; 2005 Jul 14; 23(32):4097-100. PubMed ID: 15908059
    [Abstract] [Full Text] [Related]

  • 9. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada.
    De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J, De Serres G.
    Bull World Health Organ; 1996 Jul 14; 74(4):407-11. PubMed ID: 8823963
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003.
    Soriano-Gabarró M, Toé L, Tiendrebeogo SR, Nelson CB, Dabal M, Djingarey MH, Plikaytis B, Rosenstein N, WHO Trivalent Vaccine Impact Assessment Study Group.
    Vaccine; 2007 Sep 03; 25 Suppl 1():A92-6. PubMed ID: 17517451
    [Abstract] [Full Text] [Related]

  • 11. Serologic correlates of protection for evaluating the response to meningococcal vaccines.
    Balmer P, Borrow R.
    Expert Rev Vaccines; 2004 Feb 03; 3(1):77-87. PubMed ID: 14761245
    [Abstract] [Full Text] [Related]

  • 12. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH.
    Vaccine; 2007 Jul 20; 25(29):5433-40. PubMed ID: 17560695
    [Abstract] [Full Text] [Related]

  • 13. The impact of meningococcal serogroup C conjugate vaccine in Scotland.
    Mooney JD, Christie P, Robertson C, Clarke SC.
    Clin Infect Dis; 2004 Aug 01; 39(3):349-56. PubMed ID: 15307001
    [Abstract] [Full Text] [Related]

  • 14. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun 01; 17(95):95-7. PubMed ID: 18623907
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.
    Pediatr Infect Dis J; 2009 Mar 01; 28(3):186-93. PubMed ID: 19209097
    [Abstract] [Full Text] [Related]

  • 16. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP, Struchiner CJ, Halloran ME.
    Int J Epidemiol; 1995 Oct 01; 24(5):1050-7. PubMed ID: 8557439
    [Abstract] [Full Text] [Related]

  • 17. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
    Kelly C, Arnold R, Galloway Y, O'Hallahan J.
    Am J Epidemiol; 2007 Oct 01; 166(7):817-23. PubMed ID: 17615088
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.
    De Wals P, Nguyen VH, Erickson LJ, Guay M, Drapeau J, St-Laurent J.
    Vaccine; 2004 Mar 12; 22(9-10):1233-40. PubMed ID: 15003652
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
    De Wals P, Deceuninck G, Boulianne N, De Serres G.
    JAMA; 2004 Nov 24; 292(20):2491-4. PubMed ID: 15562128
    [Abstract] [Full Text] [Related]

  • 20. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J.
    Int J Epidemiol; 2009 Apr 24; 38(2):413-8. PubMed ID: 18988650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.